Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
-
- Susan Branford
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- David T. Yeung
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Wendy T. Parker
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Nicola D. Roberts
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Leanne Purins
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Jodi A. Braley
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Haley K. Altamura
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Alexandra L. Yeoman
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Jasmina Georgievski
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Bronte A. Jamison
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Stuart Phillis
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Zoe Donaldson
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Mary Leong
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- Linda Fletcher
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;
-
- John F. Seymour
- Australasian Leukaemia and Lymphoma Group, East Melbourne, Australia;
-
- Andrew P. Grigg
- Australasian Leukaemia and Lymphoma Group, East Melbourne, Australia;
-
- David M. Ross
- School of Medicine, and
-
- Timothy P. Hughes
- School of Medicine, and
抄録
<jats:title>Key Points</jats:title><jats:p>Among patients with >10% BCR-ABL1, at 3 months, the poorest-risk group can be distinguished by the rate of BCR-ABL1 decline from baseline. Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow-up.</jats:p>
収録刊行物
-
- Blood
-
Blood 124 (4), 511-518, 2014-07-24
American Society of Hematology